Alto neuroscience announces u.s. patent granted covering alto-300 as a treatment for patients with major depressive disorder characterized by an electroencephalogram biomarker

Mountain view, calif.--(business wire)---- $anro #precisionpsychiatry--alto neuroscience, inc. (“alto”) (nyse: anro) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the u.s. patent and trademark office has granted u.s. patent number 12,226,375, with method claims pertaining to treatment of major depressive disorder (mdd) in patients with inadequate response to an antidepressant. the method includes treatment with alto-300.
ALTO Ratings Summary
ALTO Quant Ranking